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Abstract
Background. Obesity is a risk factor for cholesterol gallstone formation, but the pathogenesis of this phenomenon remains
unclear. Most human obesity is associated with diabetes and leptin-resistance. Previous studies from this laboratory have
demonstrated that diabetic leptin-resistant (Lepdb) obese mice have low biliary cholesterol saturation indices, enlarged
gallbladders and diminished gallbladder response to neurotransmitters. Recently, a novel leptin-resistant mouse strain
Leprdb-rtnd (Rotund) has been discovered. Rotund mice are also obese, diabetic, and have an abnormal leptin receptor.
Therefore, we tested the hypothesis that leptin-resistant obese Rotund mice would have large gallbladders and reduced biliary
motility.
Methods. Eight-week-old control (C57BL/6J, N=12) and Rotund leptin-resistant (Leprdb-rtnd, N=9) mice were fed a non-
lithogenic diet for four weeks. Animals were fasted and underwent cholecystectomy. Gallbladder volumes were recorded, and
contractile responses (N/cm2) to acetylcholine (1075 M), Neuropeptide Y (1078,77,76 M), and cholecystokinin
(10710,79,78,77 M) were measured. Results were analyzed using the Mann-Whitney Rank Sum Test.
Results. Compared to control mice, Rotund mice had larger body weights, higher serum glucose levels, and greater gallbladder
volumes ( p50.05). Rotund gallbladders had less contractility ( p50.05) to acetylcholine and cholecystokinin than control
mice. Responses to Neuropeptide Y were also less, but not statistically significant, in the Rotund mice.
Conclusions. These data suggest that leptin-resistant Rotund mice have (1) enlarged gallbladders with (2) diminished
contractility compared to lean control mice. Therefore, this study confirms that leptin-resistance is associated with abnormal
biliary motility and may lead to gallstone formation in leptin-resistant obesity.
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Introduction
Obesity has reached epidemic proportions in the
United States and many westernized countries. More
than 50 million US adults have a body mass index
(BMI) greater than 30 [1]. Human obesity is associated
with insulin-resistant diabetes mellitus, elevated serum
lipids, and a 3.7 times greater risk of gallstone disease
[2]. The majority of obese humans are resistant to
leptin, a hormone produced by adipocytes that induces
satiety and regulates energy expenditure. While short
forms of the leptin receptor are known to exist, leptin
is thought to work primarily on the long form receptor,
which is highly prevalent in the hypothalamus but is
also found throughout the gastrointestinal tract [3].
However, the exact relationship among obesity, leptin,
and cholesterol gallstone disease is still unknown. In
contrast, gallstone formation is known to require the
interplay of three factors, cholesterol supersaturation
of bile, cholesterol crystal pronucleators, and biliary
stasis.
The long form of the leptin receptor is highly
conserved between mice and humans and is defective
in the leptin-resistant (Lepdb) mouse model [4].
Previous studies from our laboratory have shown that
when leptin-resistant obese mice (Lepdb) are fed a
standard, low cholesterol diet, they have enlarged
gallbladders with diminished contraction to neuro-
transmitter stimulation [5]. Lepdb mice have an absent
signal transcription and translation (STAT) region of
the leptin receptor, but have a normal extracellular
domain and leptin-binding capacity as well as a normal
janus kinase (JAK) region [6]. Because JAK can
phosphorylate and activate other pathways besides
STAT [7], the Lepdb mouse model is not a true null
leptin receptor model. Recently, a new leptin-resistant
Rotund mouse has been characterized [6]. This mouse
has a nucleotide deletion resulting in a premature stop
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codon and a severely truncated leptin receptor, which
is devoid of all extracellular and intracellular domains.
Therefore, using a true leptin receptor deficient model,
we hypothesize that the Rotund mouse will also dem-
onstrate elevated glucose levels, obesity, enlarged gall-
bladder volumes, and decreased gallbladder motility
when compared to control mice.
Materials and methods
Animals and diets
To study gallbladder contraction, 12 lean control
C57BL/6J and 9 Rotund 7-week-old female mice were
obtained by special permission from a laboratory
affiliated with Jackson Laboratory (Bar Harbor, ME).
The mice were housed in cages up to 5 mice each in a
light (6 am–6 pm) and temperature (22C) controlled
environment, and isolation precautions were observed.
All mice received a standard low cholesterol CHOW
diet (Ralston Purina, St. Louis, MO) for 4 weeks. At
12 weeks of age, all mice were fasted overnight. Upon
study, mice were anesthetized with xylazine (15 mg/kg,
Phoenix Pharmaceuticals, Burnsville, MN) and keta-
mine (50 mg/kg, Phoenix Pharmaceuticals, Burnsville,
MN), weighed, and underwent cholecystectomy.
Gallbladders were placed in ice cold, preoxygenated
modified Krebs solution (in mmol/L: NaCl, 116.6;
NaCO3, 21.9; KH2PO4, 1.2; glucose, 5.4; MgCl2, 1.2;
KCl, 3.4; and CaCl2 2.5). Whole blood was obtained
by aspiration from the right heart, and livers were
removed and weighed.
Bile and Serum Glucose Analysis
Bile was aspirated from the fundus of intact gall-
bladders with a 30-gauge needle, placed into a micro-
tube, centrifuged at 15,000 rpm for 5 min at room
temperature (Micromax model, International Equip-
ment Company, Needham Heights, MA), and
measured with a micropipette. Whole blood was also
centrifuged at 15,000 rpm for 5 min at room temper-
ature to separate serum. Serum was warmed to 39C,
and glucose was measured with Freestyle glucose strips
and glucometer (Therasense, Alameda, CA).
In-vitro muscle bath
Gallbladders were sutured with 7-0 polypropylene
sutures at both ends and suspended longitudinally
in 3 mL muscle bath wells filled with modified Krebs
solution, warmed to 39C, and oxygenated with 95%
O2 and 5% CO2. Gallbladders were equilibrated at
0.025 grams of tension. Optimal length was then de-
termined by stimulation with 1075 M acetycholine
(ACh, Sigma Chemical, St. Louis, MO) at 0.025 gram
increments until maximal gallbladder contraction was
obtained. Gallbladders were maintained at their opti-
mal lengths while Neuropeptide Y (NPY, Sigmal
Chemical) at 1078, 1077, and 1076 M doses and
cholecystokinin octapeptide (CCK, Sigmal Chemical)
at 10710, 1079, 1078, and 1077 M doses were added.
Responses were measured with the Windaq/Ex
computer software (Dataq Instruments, Inc., Akron,
Ohio). After every neurotransmitter dosing and after
every 15 minutes, gallbladders were rinsed with
modified Krebs solution. Gallbladder lengths and
weights were measured and used to calculate the cross-
sectional area. Gallbladder contractile responses were
normalized for area and were expressed as Newtons per
centimeter squared (N/cm2).
Statistical analysis
Data analyses were performed with SigmaStat Statis-
tical Software (Jandel Corporation, San Rafael, CA).
All data are expressed as mean+SEM. Mouse body
and liver weights, serum glucose, gallbladder volume,
and neurotransmitter responses were analyzed by the
Mann-Whitney Rank Sum Test. A p-value less than
0.05 was regarded as significant.
Results
Body and liver weights, serum glucose, and
gallbladder volume
Data for body and liver weights, serum glucose levels
and gallbladder volumes are shown in Table I and
Figure 1. The body and liver weights of the Rotund
mice were dramatically larger than the control animals
( p50.001). In addition, the serum glucose levels of the
Rotund mice were markedly greater than the glucose
levels of the C57 control mice (421 and 160 mg/dL,
respectively, p50.01). The gallbladder volumes (Fig-
ure 1) of the Rotund mice were 19.3 mL, which were
significantly larger than 8.8 mL average gallbladder
volume of the control mice ( p50.05).
Muscle bath
Gallbladder responses to ACh are also shown in
Figure 1. The contractile responses of leptin-resistant
Rotund mice were significantly less than the responses
of the control mice (0.04 versus 0.11 N/cm2, p50.05).
Gallbladder responses to NPY at the 1078, 1077, and
1076 M concentrations are shown in Figure 2. Again,
Table I. Body weight, liver weight, and serum glucose levels for
control and rotund mice
Strain Body weight Liver weight Glucose
Control 17.2+0.4 0.87+0.05 160+23
Rotund 40.0+2.0* 2.16+0.14* 421+37*
Values are mean+SEM, body and liver weights are shown in grams,
and serum glucose levels are given as mg/dL.
* p50.01 versus Control.
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the control mice had the higher contractility than the
Rotund mice, but these differences were not statisti-
cally significant. The gallbladder responses to CCK
at the 10710, 1079, 1078 M concentrations (Figure 3)
were also significantly higher ( p50.01) in the control
mice compared to the Rotund mice.
Discussion
In this study, Rotund leptin-resistant mice fed a stan-
dard low cholesterol diet for four weeks demonstrated
heavier body and liver weights and dramatically ele-
vated serum glucose levels compared to lean C57 con-
trol mice. In addition, the Rotund mice had enlarged
gallbladders at rest, along with reduced contractility
to neurotransmitters in an in-vitro muscle bath. These
results are consistent with prior studies from our lab-
oratory with the leptin-resistant Lepdb mouse, which
also has high serum glucose levels, enlarged gall-
bladders, and diminished motility to ACh, NPY, and
CCK [5]. These similarities are not surprising, as both
of these mice have defective leptin receptors and
similar, but not identical, phenotypes.
The defect in motility demonstrated in both of
the leptin-resistant obese mice is also similar to our
findings with Lepob mice, which lack the ability to pro-
duce leptin and, therefore, are leptin-deficient. Lepob
mice also have severe insulin resistant diabetes, hyper-
triglyceridemia, and enlarged gallbladder volumes [8].
These mice also have dramatically reduced gallbladder
contractility to neurotransmitter stimulation in an
in-vitro muscle bath [8] that is restored with leptin
administration and glucose normalization [9]. Hetero-
zygous leptin-deficient (Lepob+/7) mice are pheno-
typically lean, not diabetic, and have slightly enlarged
gallbladders. They have gallbladder motility that is less
than control mice, but greater than the leptin-deficient
Lepob or the leptin-resistant Lepdb mice [10]. We have
also shown that Agouti yellow (AY) mice which are
overweight, but have normal leptin physiology and
slightly elevated serum sugars, have gallbladder mo-
tility that resembles the C57 control mice [5].
Because of the similar findings of gallbladder en-
largement and dysmotility of the leptin-deficient Lepob
and both the Lepdb and Rotund leptin-resistant mice,
leptin or obesity per se may not be directly responsible
for these effects. Bouchard et al. reported that a dys-
functional leptin mechanism may indeed be protective
against gallstone formation because of relatively normal
biliary lipids [11]. Further analysis of our gallbladder
motility studies revealed that decreasing gallbladder
contractility correlated significantly with both increas-
ing serum glucose and triglyceride levels as well as body
weight [10]. Thus, hyperglycemia or hyperlipidemia
may be the link between obesity, leptin, and cholesterol
gallstone disease. In fact, a recent study has dem-
onstrated that while consumption of a high fat diet
increases resistin, a hormone known to increase insulin
resistance, leptin activation of the long leptin receptor
ameliorates insulin resistance by downregulation of
resistin [12]. These authors also demonstrated that
leptin administration to Lepdb animals did not down-
regulate resistin and concluded that a functional long
form of the leptin receptor was required [12]. These
findings also suggest that leptin plays a role in con-
trolling diabetes, and these leptin dysfunctional mice
may have gallbladder dysmotility as a consequence of
their diabetes.
Figure 1. Gallbladder volume and response to acetylcholine
stimulation.
Figure 2. Gallbladder response to neuropeptide Y.
Figure 3. Gallbladder response to cholecystokinin.
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Gallbladder contraction is initiated by depolariza-
tion of intrinsic cholinergic neurons as well as by direct
binding of neurotransmitters to myocyte surface
receptors [13–15]. The cholinergic ganglionic plexus is
intrinsic to the gallbladder, lying between the serosa
and muscle layers [15]. These postganglionic nerves
are present in the whole organ muscle bath, and prior
studies have shown that cholecystokinin can readily
access the subserosal gallbladder ganglia and activate
the intrinsic cholinergic postganglionic nerves [15,16].
Acetylcholine, which is released from the cholinergic
nerves upon depolarization, causes autoexitation of the
nerves and also potentiates contraction [17]. Because
CCK and ACh act via a neuronal mechanism, diabetic
neuropathy may be an explanation for the abnormal
gallbladder motility observed in Lepob, Lepdb, and
Rotund mice.
In addition to neuronally activated gallbladder
contraction, direct binding of neurotransmitters to
myocyte surface muscarinic [17] and CCK-A [13] re-
ceptors also initiates gallbladder contraction. We have
previously demonstrated that gallbladder myocytes
from both the leptin-deficient Lepob mice and the
leptin-resistant Lepdb mice are foreshortened, perhaps
due to water loss from hyperglycemia [18]. In addition,
the myocytes from Lepob and Lepdb mice have a re-
duced response to CCK compared to lean control
myocytes [18].
Our observations with the Lepob, Lepdb, and Rotund
mice are also consistent with many gallbladder
imaging studies in human diabetic patients which
have reported that these patients have larger resting
gallbladder volumes [19–21] and reduced contraction
in response to a meal [19,20]. We also have recently
demonstrated that non-obese diabetic NOD mice,
which are insulin deficient, have enlarged gallbladders
with gallbladder dysmotility which worsens with
progression of diabetes [22]. Diabetes may affect, in
part, alterations in the density or sensitivity of ACh
or CCK receptors, or may alter access to these recep-
tors. Advanced glycation end products (AGEP) occur
when elevated sugars react non-enzymatically and
cause covalent crosslinking of collagens and protein
matrix [23] and may also inhibit gallbladder contrac-
tility by stiffening gallbladder myocytes or connective
tissue, or by preventing egress of CCK to the gall-
bladder.
In addition to hyperglycemia, we have demonstrated
that decreasing gallbladder motility correlates with
increasing hypertriglyceridemia [10]. Hypertyglyceri-
demia often occurs in diabetes as AGEP can cause
oxidation of low-density lipoproteins (LDL) and pre-
vent recognition by the LDL receptor [23]. Whether
alone, or in conjunction with diabetes, elevated serum
fats may promote free radical formation and inflam-
mation in the gallbladder wall, interfering with con-
traction. In theory, elevated serum lipids may also
influence gallbladder bile composition and gallstone
formation.
Previous studies with the Lepob and Lepdb mice
demonstrate that their bile is unsaturated with
cholesterol on a standard low cholesterol diet [24,25].
However, with consumption of a high cholesterol diet,
similar to the diet consumed by many obese humans,
gallbladder bile of the Lepob and Lepdb mice becomes
nearly saturated with cholesterol [10,26]. In addition,
bile from the Lepob mice has faster cholesterol crys-
tallization and growth when compared to control mice
[24], while Lepdb mice have prolonged crystal obser-
vation times, and decreased crystal growth and mass
[26]. Because of the small numbers of Rotund animals
available, we were not able to perform bile or crystal
analysis, but we would speculate that their bile
composition and physiology would be similar to the
Lepdb mice.
As the human population becomes more obese and
suffers the comorbidities associated with obesity,
cholesterol gallstone disease will also pose a larger
healthcare problem. Our studies suggest that the rela-
tionship between obesity and gallstone disease is
indirectly influenced by leptin and its receptors, and
the direct effects may be mediated by diabetes and/or
lipid disorders. If present trends continue, elucidation
of the exact mechanisms for cholesterol gallstone
formation will become an even more important goal.
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